Stephane Birkle
Nantes, 44000, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Targeting GD2 with CAR-T Cell Therapy in Neuroblastoma: Updates, Challenges, and Future Perspectives.
Journal: Current oncology reports
Published: August 10, 2025
Biology of GD2 ganglioside: implications for cancer immunotherapy.
Journal: Frontiers in pharmacology
Published: June 29, 2023
Public Health Impact of Using Biosimilars, Is Automated Follow up Relevant?
Journal: International journal of environmental research and public health
Published: November 21, 2020
SIRPα-specific monoclonal antibody enables antibody-dependent phagocytosis of neuroblastoma cells.
Journal: Cancer immunology, immunotherapy : CII
Published: September 10, 2020
Impairing temozolomide resistance driven by glioma stem-like cells with adjuvant immunotherapy targeting O-acetyl GD2 ganglioside.
Journal: International journal of cancer
Published: February 14, 2019
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation.
Journal: Journal of visualized experiments : JoVE
Published: February 09, 2019
Targeting O-Acetyl-GD2 Ganglioside for Cancer Immunotherapy.
Journal: Journal of immunology research
Published: August 15, 2016
Targeting and killing glioblastoma with monoclonal antibody to O-acetyl GD2 ganglioside.
Journal: Oncotarget
Published: September 29, 2015
Chimeric antibody c.8B6 to O-acetyl-GD2 mediates the same efficient anti-neuroblastoma effects as therapeutic ch14.18 antibody to GD2 without antibody induced allodynia.
Journal: PloS one
Published: November 01, 2013
Last Updated: 09/26/2026